• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.LncRNA LEF1-AS1 沉默通过削弱 CEBPB 与 CDCA7 的相互作用来减少 EZH2 的表达,从而延缓肝癌的发展。
Cell Cycle. 2020 Apr;19(8):870-883. doi: 10.1080/15384101.2020.1731052. Epub 2020 Mar 16.
2
Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.长链非编码 RNA UPK1A-AS1 提示肝细胞癌预后不良,并通过与 EZH2 相互作用促进细胞增殖。
J Exp Clin Cancer Res. 2020 Oct 29;39(1):229. doi: 10.1186/s13046-020-01748-y.
3
Silencing of long noncoding RNA LEF1-AS1 prevents the progression of hepatocellular carcinoma via the crosstalk with microRNA-136-5p/WNK1.长链非编码 RNA LEF1-AS1 的沉默通过与 microRNA-136-5p/WNK1 的串扰防止肝细胞癌的进展。
J Cell Physiol. 2020 Oct;235(10):6548-6562. doi: 10.1002/jcp.29503. Epub 2020 Feb 18.
4
Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.长链非编码RNA LEF1-AS1作为微小RNA-10a-5p的调节因子,通过激活AKT信号通路增强MSI1表达并促进肝癌细胞的化学抗性。
J Cell Biochem. 2021 Jan;122(1):86-99. doi: 10.1002/jcb.29833. Epub 2020 Aug 12.
5
Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway.下调的长链非编码 RNA TP73-AS1 通过 PTEN/Akt 信号通路降低肝癌的放射抵抗性。
Cell Cycle. 2019 Nov;18(22):3177-3188. doi: 10.1080/15384101.2019.1671089. Epub 2019 Sep 29.
6
Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.长链非编码RNA SPRY4-IT1的过表达通过激活肝细胞癌中的EZH2促进肿瘤细胞增殖和侵袭。
Biomed Pharmacother. 2017 Jan;85:348-354. doi: 10.1016/j.biopha.2016.11.035. Epub 2016 Nov 28.
7
LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway.长链非编码 RNA DBH-AS1 通过 FAK/Src/ERK 通路靶向 miR-138 促进肝癌的发生。
Biomed Pharmacother. 2018 Nov;107:824-833. doi: 10.1016/j.biopha.2018.08.079. Epub 2018 Aug 22.
8
ZSCAN16-AS1 expedites hepatocellular carcinoma progression via modulating the miR-181c-5p/SPAG9 axis to activate the JNK pathway.ZSCAN16-AS1 通过调节 miR-181c-5p/SPAG9 轴激活 JNK 通路促进肝细胞癌进展。
Cell Cycle. 2021 Jun;20(12):1134-1146. doi: 10.1080/15384101.2021.1919828. Epub 2021 Jun 7.
9
The lncRNA Promotes Hepatocellular Carcinoma Cell Cycle Progression by Regulating the HuR/CDK4 Axis.长链非编码 RNA 通过调控 HuR/CDK4 轴促进肝癌细胞周期进程。
DNA Cell Biol. 2021 Oct;40(10):1278-1289. doi: 10.1089/dna.2021.0235. Epub 2021 Sep 24.
10
LncRNA FOXD2-AS1 plays an oncogenic role in hepatocellular carcinoma through epigenetically silencing CDKN1B(p27) via EZH2.长链非编码 RNA FOXD2-AS1 通过 EZH2 表观遗传沉默 CDKN1B(p27) 在肝细胞癌中发挥致癌作用。
Exp Cell Res. 2019 Jul 15;380(2):198-204. doi: 10.1016/j.yexcr.2019.04.016. Epub 2019 Apr 17.

引用本文的文献

1
Mechanism of LEF1-AS1 regulating HUVEC cells by targeting miR-489-3p/S100A11 axis.LEF1-AS1 通过靶向 miR-489-3p/S100A11 轴调控 HUVEC 细胞的机制。
PeerJ. 2023 Nov 1;11:e16128. doi: 10.7717/peerj.16128. eCollection 2023.
2
Making Sense of Antisense lncRNAs in Hepatocellular Carcinoma.解析肝细胞癌中的反义 lncRNA。
Int J Mol Sci. 2023 May 17;24(10):8886. doi: 10.3390/ijms24108886.
3
Research into the characteristic molecules significantly affecting liver cancer immunotherapy.研究对肝癌免疫治疗有显著影响的特征分子。
Front Immunol. 2023 Feb 13;14:1029427. doi: 10.3389/fimmu.2023.1029427. eCollection 2023.
4
CDCA7 promotes TGF-β-induced epithelial-mesenchymal transition via transcriptionally regulating Smad4/Smad7 in ESCC.CDCA7 通过转录调控 ESCC 中的 Smad4/Smad7 促进 TGF-β诱导的上皮-间充质转化。
Cancer Sci. 2023 Jan;114(1):91-104. doi: 10.1111/cas.15560. Epub 2022 Nov 14.
5
Long Non-Coding LEF1-AS1 Sponge miR-5100 Regulates Apoptosis and Autophagy in Gastric Cancer Cells via the miR-5100/DEK/AMPK-mTOR Axis.长链非编码 LEF1-AS1 通过 miR-5100/DEK/AMPK-mTOR 轴调控胃癌细胞凋亡和自噬。
Int J Mol Sci. 2022 Apr 26;23(9):4787. doi: 10.3390/ijms23094787.
6
Single-Cell RNA Sequencing Reveals the Role of Phosphorylation-Related Genes in Hepatocellular Carcinoma Stem Cells.单细胞RNA测序揭示磷酸化相关基因在肝癌干细胞中的作用。
Front Cell Dev Biol. 2022 Jan 4;9:734287. doi: 10.3389/fcell.2021.734287. eCollection 2021.
7
Current Research Progress of the Role of LncRNA LEF1-AS1 in a Variety of Tumors.LncRNA LEF1-AS1在多种肿瘤中作用的当前研究进展
Front Cell Dev Biol. 2021 Dec 20;9:750084. doi: 10.3389/fcell.2021.750084. eCollection 2021.
8
Development of a novel five-lncRNA prognostic signature for predicting overall survival in elderly patients with breast cancer.一种新型五长链非编码 RNA 预后标志物的开发,用于预测老年乳腺癌患者的总生存期。
J Clin Lab Anal. 2022 Jan;36(1):e24172. doi: 10.1002/jcla.24172. Epub 2021 Dec 11.
9
LINC00035 Transcriptional Regulation of SLC16A3 via CEBPB Affects Glycolysis and Cell Apoptosis in Ovarian Cancer.LINC00035 通过 CEBPB 对 SLC16A3 的转录调控影响卵巢癌的糖酵解和细胞凋亡
Evid Based Complement Alternat Med. 2021 Oct 11;2021:5802082. doi: 10.1155/2021/5802082. eCollection 2021.
10
Identification of hub genes associated with prognosis, diagnosis, immune infiltration and therapeutic drug in liver cancer by integrated analysis.基于整合分析鉴定与肝癌预后、诊断、免疫浸润和治疗药物相关的枢纽基因。
Hum Genomics. 2021 Jun 29;15(1):39. doi: 10.1186/s40246-021-00341-4.

本文引用的文献

1
LEF1-AS1 contributes to proliferation and invasion through regulating miR-544a/ FOXP1 axis in lung cancer.Lef1 反义 RNA1 通过调控 miR-544a/FOXP1 轴促进肺癌的增殖和侵袭。
Invest New Drugs. 2019 Dec;37(6):1127-1134. doi: 10.1007/s10637-018-00721-z. Epub 2019 Feb 8.
2
Long noncoding RNA LEF1-AS1 silencing suppresses the initiation and development of prostate cancer by acting as a molecular sponge of miR-330-5p via LEF1 repression.长链非编码 RNA LEF1-AS1 通过抑制 LEF1 发挥 miR-330-5p 分子海绵的作用,抑制前列腺癌的发生和发展。
J Cell Physiol. 2019 Aug;234(8):12727-12744. doi: 10.1002/jcp.27893. Epub 2019 Jan 5.
3
Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers.19 号染色体 miRNA 簇和 CEBPB 表达特异性标记并可能驱动三阴性乳腺癌。
PLoS One. 2018 Oct 18;13(10):e0206008. doi: 10.1371/journal.pone.0206008. eCollection 2018.
4
Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.CDCA7 过表达预示着三阴性乳腺癌不良预后并诱导 EZH2 介导的进展。
Int J Cancer. 2018 Nov 15;143(10):2602-2613. doi: 10.1002/ijc.31766. Epub 2018 Sep 19.
5
Long non-coding RNAs in ovarian cancer.长链非编码 RNA 在卵巢癌中的作用。
J Exp Clin Cancer Res. 2018 Jun 19;37(1):120. doi: 10.1186/s13046-018-0793-4.
6
CDCA7 is a critical mediator of lymphomagenesis that selectively regulates anchorage-independent growth.CDCA7 是淋巴瘤发生的关键介质,它选择性地调节锚定非依赖性生长。
Haematologica. 2018 Oct;103(10):1669-1678. doi: 10.3324/haematol.2018.188961. Epub 2018 Jun 7.
7
C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.C/EBPβ 通过重编程 H3K79 甲基化增强卵巢癌细胞的铂耐药性。
Nat Commun. 2018 Apr 30;9(1):1739. doi: 10.1038/s41467-018-03590-5.
8
Identification of The Aberrantly Expressed LncRNAs in Hepatocellular Carcinoma: A Bioinformatics Analysis Based on RNA-sequencing.肝细胞癌中异常表达的长链非编码 RNA 的鉴定:基于 RNA-seq 的生物信息学分析。
Sci Rep. 2018 Mar 29;8(1):5395. doi: 10.1038/s41598-018-23647-1.
9
Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC).抗 miR-17 疗法可延缓 MYC 驱动的肝细胞癌(HCC)的肿瘤发生。
Oncotarget. 2017 Nov 9;9(5):5517-5528. doi: 10.18632/oncotarget.22342. eCollection 2018 Jan 19.
10
HELLS and CDCA7 comprise a bipartite nucleosome remodeling complex defective in ICF syndrome.HELLS 和 CDCA7 组成二分体核小体重塑复合物,该复合物在 ICF 综合征中存在缺陷。
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E876-E885. doi: 10.1073/pnas.1717509115. Epub 2018 Jan 16.

LncRNA LEF1-AS1 沉默通过削弱 CEBPB 与 CDCA7 的相互作用来减少 EZH2 的表达,从而延缓肝癌的发展。

LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.

机构信息

Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, P. R. China.

出版信息

Cell Cycle. 2020 Apr;19(8):870-883. doi: 10.1080/15384101.2020.1731052. Epub 2020 Mar 16.

DOI:10.1080/15384101.2020.1731052
PMID:32178558
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7217375/
Abstract

Hepatocellular carcinoma (HCC) is recognized for its high mortality rate worldwide. Based on intensive studies, long non-coding RNA (lncRNA) expression exerts significant effects on tumor suppression. Herein, we investigated the molecular mechanism of lymphoid enhancer-binding factor-1 antisense RNA 1 (LEF1-AS1) in HCC cells. Microarray-based gene expression analysis was adopted to predict and verify the differentially expressed genes in HCC, which predicted cell division cycle-associated 7 (CDCA7) and LEF1-AS1 to be highly expressed in HCC. The expression of LEF1-AS1, CDCA7, CCAAT/enhancer-binding protein beta (CEBPB) and enhancer of zeste homolog 2 (EZH2) was determined by means of reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot analysis. LncMap was used to predict the lncRNA-transcription factor-gene interaction in HCC. ChIP, RIP assay and dual luciferase reporter gene assay were employed to verify the relationship between the transcription factor and gene. Silencing of LEF1-AS1 could downregulate CDCA7 expression through CEBPB. Overexpression of LEF1-AS1, EZH2 and CDCA7 promoted proliferation and invasion in HCC cells. LEF1-AS1 promoted CDCA7 expression to further upregulate EZH2. Tumor formation in nude mice was assessed to verify the experimental results. Silencing of LEF1-AS1 inhibited the growth of tumors . Collectively, silencing LEF1-AS1 inhibited the proliferation and invasion of HCC cells by down-regulating EZH2 through the CEBPB-CDCA7 signaling pathway, which provides scientific evidence for the treatment of HCC.: HCC: Hepatocellular carcinoma; lncRNA: long non-coding RNA; LEF1-AS1: lymphoid enhancer-binding factor-1 antisense RNA 1; EZH2: enhancer of zeste homolog 2; CDCA7: cell division cycle-associated 7; GEO: Gene Expression Omnibus; NC: negative control; oe: overexpressed; RT-qPCR: reverse transcription quantitative polymerase chain reaction; PBS: phosphate buffered saline; HRP: horseradish peroxidase; OD: optical density; RIP: Radioimmunoprecipitation; ChIP: Chromatin immunoprecipitation; WT: wild type.

摘要

肝细胞癌 (HCC) 是全球高死亡率的癌症。基于深入研究,长链非编码 RNA (lncRNA) 的表达对肿瘤抑制具有显著影响。在此,我们研究了淋巴增强结合因子 1 反义 RNA 1 (LEF1-AS1) 在 HCC 细胞中的分子机制。采用基于微阵列的基因表达分析来预测和验证 HCC 中差异表达的基因,结果预测细胞分裂周期相关蛋白 7 (CDCA7) 和 LEF1-AS1 在 HCC 中高表达。通过逆转录定量聚合酶链反应 (RT-qPCR) 和蛋白质印迹分析确定 LEF1-AS1、CDCA7、CCAAT/增强子结合蛋白β (CEBPB) 和增强子的锌指蛋白 2 (EZH2) 的表达。LncMap 用于预测 HCC 中的 lncRNA-转录因子-基因相互作用。ChIP、RIP 测定和双荧光素酶报告基因测定用于验证转录因子与基因之间的关系。沉默 LEF1-AS1 可通过 CEBPB 下调 CDCA7 的表达。过表达 LEF1-AS1、EZH2 和 CDCA7 可促进 HCC 细胞的增殖和侵袭。LEF1-AS1 促进 CDCA7 的表达,从而进一步上调 EZH2。裸鼠肿瘤形成实验验证实验结果。沉默 LEF1-AS1 抑制肿瘤生长。综上所述,沉默 LEF1-AS1 通过 CEBPB-CDCA7 信号通路下调 EZH2 抑制 HCC 细胞的增殖和侵袭,为 HCC 的治疗提供了科学依据。